|
|
Sympathetic cardiac function in early sepsis: Noninvasive evaluation with [ 123 I]- meta -iodobenzylguanidine ( 123 I-MIBG) in vivo SPECT imaging
|
|
|
|
|
نویسنده
|
Clerc Romain ,Doll Sophia ,Riou Laurent M. ,Perret Pascale ,Broisat Alexis ,Soubies Audrey ,Desruet Marie-Dominique ,Fagret Daniel ,Schwebel Carole ,Ghezzi Catherine
|
منبع
|
journal of nuclear cardiology - 2018 - دوره : 25 - شماره : 2 - صفحه:483 -491
|
چکیده
|
Sympathetic system abnormalities have been reported in sepsis-related cardiac dysfunction. the present study aimed at evaluating the potential of the norepinephrine radiolabeled analogue [123i]-meta-iodobenzylguanidine (123i-mibg) for the noninvasive assessment of modifications in cardiac sympathetic activity occurring in lipopolysaccharide (lps)-induced experimental acute sepsis by single-photon emission computed tomographic imaging (spect). sepsis was induced in male wistar rats by intraperitoneal injection of 10 mg·kg−1 lipopolysaccharide (n = 16), whereas control animals (n = 7) were injected with vehicle (nacl 0.9%). echocardiography in lps-injected animals (n = 8) demonstrated systolic and diastolic cardiac dysfunction. 123i-mibg was injected 1 hour after lps or vehicle administration (n = 8 and 7, respectively), and in vivo spect imaging was performed early and late (20 and 180 minutes) after tracer injection prior to animal euthanasia and ex vivo assessment of 123i-mibg biodistribution. global and 17-segment spect image analysis indicated that early 123i-mibg activity was not affected by lps treatment, whereas late cardiac tracer activity was significantly decreased in lps-treated animals. consequently, the cardiac washout of 123i-mibg was significantly higher in lps-treated (63.3% ± 4.0%) than that in control animals (56.7% ± 5.8%) (p < .05). sepsis-induced modifications in cardiac sympathetic nervous system activity were evidenced by noninvasive in vivo 123i-mibg spect imaging.
|
کلیدواژه
|
Basic science ,MIBG imaging ,experimental sepsis ,microSPECT imaging
|
آدرس
|
INSERM U1039, Radiopharmaceutiques Biocliniques, France. Université Grenoble Alpes, France, INSERM U1039, Radiopharmaceutiques Biocliniques, France. Université Grenoble Alpes, France, INSERM U1039, Radiopharmaceutiques Biocliniques, France. Université Grenoble Alpes, France. Faculté de Médecine de Grenoble, France, INSERM U1039, Radiopharmaceutiques Biocliniques, France. Université Grenoble Alpes, France, INSERM U1039, Radiopharmaceutiques Biocliniques, France. Université Grenoble Alpes, France, INSERM U1039, Radiopharmaceutiques Biocliniques, France. Université Grenoble Alpes, France, INSERM U1039, Radiopharmaceutiques Biocliniques, France. Grenoble University Hospital, Nuclear Medicine Department, France, INSERM U1039, Radiopharmaceutiques Biocliniques, France. Grenoble University Hospital, Nuclear Medicine Department, France, INSERM U1039, Radiopharmaceutiques Biocliniques, France. Université Grenoble Alpes, France. Grenoble University Hospital, Intensive Care Unit, France, INSERM U1039, Radiopharmaceutiques Biocliniques, France. Université Grenoble Alpes, France
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|